Feelings of social isolation and financial toxicity take an especially high toll on patients with LAHNC, and assessing patients for these issues is essential to achieve optimal care.
Feelings of social isolation and financial toxicity take an especially high toll on patients with locally advanced head and neck cancer (LAHNC), and assessing patients for these issues is essential to achieve optimal patient care, according to researchers presenting their study findings at the 2016 Multidisciplinary Head and Neck Cancer Symposium.
LAHNC is characterized by high morbidity and high medical costs. The researchers also found such burdens affect patients’ ability to stay on medication, minimize hospital stays, and achieve optimal health outcomes.
In addition, a majority of patients with LAHNC resorted to life-altering strategies to cope with the financial burden of their treatment, including drawing down savings (62%), borrowing money or using credit (42%), selling possessions (25%), and relying on family members to work longer hours (23%), in order to compensate for the patient’s lower earnings capability. More than two-thirds of study participants (69%) said they resorted to one or more of these strategies.
“Patients with high perceived social isolation have more days in which they take less medication. They have suboptimal medication adherence, they have a higher number of missed appointments, and they also have longer stays in the hospital compared to their peers,” said Sunny Kung, lead author on the study and a second-year student at the University of Chicago’s Pritzker School of Medicine. Increased loneliness caused by isolation should also be considered a risk factor, she said.
Approximately 60,000 new cases of head and neck cancer are diagnosed each year. Despite a high cure rate (80% at 5 years), physical morbidity and financial toxicity take a heavy and a lasting toll, Kung said.
The study followed 73 patients with LAHNC by doing monthly surveys over a 6-month period. Most patients in the study were male (78%), Caucasian (74%) and covered by private health insurance (54.8%).
“Those with higher out-of-pocket costs were more likely to use [cost-coping] strategies,” Kung said. Patients had average out-of-pocket costs of $1589, of which $1287 was attributable to direct medical costs that included deductibles, hospital bills, and doctor’s visits; the remainder, $303, was for insurance premiums.
The study also examined the prevalence of perceived social isolation among LAHNC patients and its association with socioeconomic factors and healthcare utilization. Researchers identified perceived isolation in 7 of the 73 patients (9.5%) prior to treatment. Patients who reported high perceived social isolation were more likely to be unemployed and divorced or widowed.
Among all patients enrolled in the study, the average number of days taking less medication was 6.99, whereas for those with low/moderate perceived social isolation the average was 5.45 days; for those with high perceived social isolation the average was 21.4 days.
The respective numbers of days for missed appointments was for all participants, 3.4; low/moderate, 3.02; high, 7. Inpatient hospital days also trended higher for the high perceived social isolation patients.
Overall, study authors concluded the following, based on their findings:
“Physical side effects are not the only ones our patients endure,” said Kung. ”Our findings indicate that the majority of our patients have adopted or will adopt strategies to cope with the financial side effects of their care.
“Social interventions can be introduced for patients who feel isolated in order to minimize financial burden while maximizing effective health care utilization. For example, providers can work with patient navigators to improve adherence to medical care among vulnerable populations.”
Kung S, O'Connor J, Yap BJ, et al. Cost-coping strategies and perceived social isolation in locally advanced head and neck cancer. Presented at: 2016 Multidisciplinary Head and Neck Cancer Symposium; February 18-20, 2016; Scottsdale, AZ. Abstract 323.
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML